TNFRSF12A and neoplasm: Some TweakR-expressing tumor cell lines, such as HCT116 and DLD-1, were not sensitive to enavatuzumab treatment in vivo (Figure 2(b)), though both cell lines were effectively killed via ADCC in vitro with enavatuzumab.